BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

ADELA Phase III Trial Combines Elacestrant and Everolimus to Tackle Advanced ER+/HER2- Breast Cancer with ESR1 Mutations

ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breas...

December 13, 2024 | News

GNT Pharma Announces Promising Nelonemdaz Results, Initiates Global Phase 3 Stroke Trials

** IND submitted to the FDA showing significantly improved patient condition when administered within 70 minutes of arrival at the Emergency Room ** *Mult...

December 12, 2024 | News

Duke Street Bio Initiates Phase I Trial of Highly Selective PARP1 Inhibitor DSB2455 for Solid Tumours

Duke Street Bio Ltd, a precision medicine biotech developing next-generation small molecule cancer therapies, is pleased to announce that the first patient...

December 12, 2024 | News

Asahi Kasei Pharma Expands Global Reach with Exclusive Anti-CX3CR1 Antibody License

Asahi Kasei Pharma has taken another significant step toward becoming a leading global specialty pharmaceutical company by entering an exclusive license ag...

December 12, 2024 | News

Agilent Technologies Achieves EU IVDR Certification for PD-L1 IHC 28-8 pharmDx

-Agilent Technologies Inc. announced the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for PD-L1...

December 11, 2024 | News

GHIT Fund and WHO Strengthen Partnership to Combat Neglected Tropical Diseases

The Global Health Innovative Technology (GHIT) Fund and the World Health Organization (WHO) have signed a memorandum of understanding (MoU) to furthe...

December 11, 2024 | News

Hansa Biopharma Completes Phase 3 Trial Enrollment Ahead of Schedule for Rare Autoimmune Disease

Hansa Biopharma, "Hansa" announced it has completed the enrolment of patients in the GOOD-IDES-02 trial, a global pivotal Phase 3 trial in anti-glomerular ...

December 06, 2024 | News

NTC Announces Positive Phase II Results for NTC014 in Bacterial Conjunctivitis Treatment

NTC, an international R&D focused pharmaceutical company headquartered in Italy, presents positive results from Phase II MIRAKLE study, a mul...

December 06, 2024 | News

QIAGEN Launches Industry-First Custom Digital PCR and NGS Panel Design Tools for Advanced Microbial Applications

QIAGEN introduces market’s first customizable digital PCR assay design tool with advanced design algorithms tailored for diverse microbial applicat...

November 29, 2024 | News

Vaxxas Expands Global Patent Portfolio to 42, Securing Exclusive Rights to HD-MAP Vaccination Technology

-Vaxxas, a clinical-stage biotechnology company, has expanded its global intellectual property portfolio to 42 patents, supporting its exclusive claim to m...

November 25, 2024 | News

GenScript Biotech Hosts European Debut of Global Forum, Driving Collaboration in Cell and Gene Therapy Innovation

GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the European debut of its GenS...

November 22, 2024 | Report

Samsung Biologics Secures USD 668 Million in Manufacturing Deals with Europe, Surpasses USD 4 Billion in 2024 Global Contract Value

The company will provide manufacturing services through 2031 in deals worth over USD 668 million Samsung Biologics' cumulative contract value for 2...

November 20, 2024 | News

South Korea’s Celltrion Acquires iQone Healthcare Switzerland to Boost Direct Commercialization of Biosimilars in Europe

Celltrion announces acquisition of iQone Healthcare Switzerland, accelerating direct commercialization of its biosimilars in the European region T...

November 18, 2024 | News

SEKISUI Diagnostics Completes £15.7 Million cGMP Expansion for Enhanced Microbial Drug Substance Manufacturing in the UK

SEKISUI Diagnostics' microbial CDMO business announces it has completed construction of its £15.7 million ($20.7 million) cGMP capacity expansion&nbs...

November 15, 2024 | News

Stay Connected